Association between KRAS mutations and the endoscopic and histopathological features of colorectal adenomatous polyps

Le Thi Ngoc Huyen, Nguyen Thanh Liem, Kha Huu Nhan, Thai Thi Hong Nhung, Nguyen Phan Hai Sam, La Vinh Phuc, Nguyen The Bao, Tran Y Duc, Luong Thi Thuy Loan, Dang Nhu Lan, Nguyen Tien Thien, Huynh Van Loc, Huynh Hieu Tam

Nội dung chính của bài viết

Tóm tắt

Colorectal adenomatous polyps are the principal premalignant lesions in colorectal carcinogenesis, and the combined evaluation of endoscopic features, histopathological characteristics, and molecular alterations such as KRAS mutations may help identify lesions with higher-risk features. This analytical cross-sectional study included 123 colorectal adenomatous polyps treated at Can Tho University of Medicine and Pharmacy Hospital from June 2024 to January 2026 to determine the prevalence of KRAS mutations and to assess the associations between KRAS mutation status and endoscopic and histopathological features. KRAS mutations were detected in 38.2% of polyps, predominantly at codon 12 (26.8%), followed by codon 13 (11.4%), no codon 61 mutation was identified. In univariable analyses, KRAS mutation status was associated with a nodular/lobulated surface, JNET type IIB–III classification, polyp size ≥10 mm, tubulovillous adenoma histology, and high-grade dysplasia. In multivariable logistic regression, only polyp size ≥10 mm (OR = 5.71; 95% CI: 2.08–15.67; p < 0.001) and high-grade dysplasia (OR = 6.81; 95% CI: 1.27–36.36; p = 0.025) remained significantly associated with KRAS mutation status. These findings suggest that KRAS mutations may be associated with more advanced features of colorectal adenomatous polyps, particularly larger size and high-grade dysplasia.

Chi tiết bài viết

Tài liệu tham khảo

1. Nguyen LH, Goel A, Chung DC. Pathways of Colorectal Carcinogenesis. Gastroenterology. 2020; 158(2): 291-302. doi:10.1053/j.gastro.2019.08.059.
2. Sano Y, Tanaka S, Kudo SE, et al. Narrow-band imaging (NBI) magnifying endoscopic classification of colorectal tumors proposed by the Japan NBI Expert Team. Dig Endosc. 2016; 28(5): 526-533. doi:10.1111/den.12644.
3. Uniyal P, Kashyap VK, Behl T, Parashar D, Rawat R. KRAS mutations in cancer: understanding signaling pathways to immune regulation and the potential of immunotherapy. Cancers (Basel). 2025; 17(5): 785. doi:10.3390/cancers17050785.
4. Casacuberta-Serra S, González-Larreategui Í, Capitán-Leo D, Soucek L. MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer. Signal Transduct Target Ther. 2024; 9: 205. doi:10.1038/s41392-024-01907-z.
5. Maltzman T, Knoll K, Martinez ME, et al. Ki-ras proto-oncogene mutations in sporadic colorectal adenomas: relationship to histologic and clinical characteristics. Gastroenterology. 2001; 121(2): 302-309. doi:10.1053/gast.2001.26278.
6. Lorentzen JA, Grzyb K, De Angelis PM, Hoff G, Eide TJ, Andresen PA. Oncogene Mutations in Colorectal Polyps Identified in the Norwegian Colorectal Cancer Prevention (NORCCAP) Screening Study. Clin Med Insights Pathol. 2016; 9: 19-28. doi:10.4137/CPath.s40143.
7. Yadamsuren EA, Nagy S, Pajor L, Lacza A, Bogner B. Characteristics of advanced- and non advanced sporadic polypoid colorectal adenomas: correlation to KRAS mutations. Pathol Oncol Res. 2012; 18(4): 1077-1084. doi:10.1007/s12253-012-9547-3.
8. Metz AJ, Bourke MJ, Moss A, et al. A correlation of the endoscopic characteristics of colonic laterally spreading tumours with genetic alterations. Eur J Gastroenterol Hepatol. 2013; 25(3): 319-326. doi:10.1097/MEG.0b013e32835b57e7.
9. Tran TH, Nguyen LT, Nguyen QD, Duong QH. Research on KRAS mutations in patients with colorectal polyps larger than 10 mm. Journal of Military Pharmaco-medicine. 2022; 47(7): 145-155. doi:10.56535/jmpm.v47i7.84.
10. Martínez-Roca A, Cubiella J, García-Heredia A, et al. Prediction of metachronous advanced colorectal neoplasia by KRAS mutation in polyps. United European Gastroenterol J. 2024; 12(9): 1179-1189. doi:10.1002/ueg2.12667.
11. Le NQ, Huynh TM, Vo DTN, et al. Diagnostic performance of the Japanese Narrow-band imaging expert team classification system using dual focus magnification in real-time Vietnamese setting. Medicine (Baltimore). 2024; 103(27): e38752. doi:10.1097/MD.0000000000038752.
12. Yi C, Huang Y, Yu X, et al. Clinicopathologic distribution of KRAS and BRAF mutations in a Chinese population with colorectal cancer precursor lesions. Oncotarget. 2016; 7(13): 17265-17274. doi:10.18632/oncotarget.7504.
13. Kaya C, Dorsaint P, Mercurio S, et al. Limitations of Detecting Genetic Variants from the RNA Sequencing Data in Tissue and Fine-Needle Aspiration Samples. Thyroid. 2021; 31(4): 589-595. doi:10.1089/thy.2020.0307.
14. Ferreira A, Pereira F, Reis C, Oliveira MJ, Sousa MJ, Preto A. Crucial Role of Oncogenic KRAS Mutations in Apoptosis and Autophagy Regulation: Therapeutic Implications. Cells. 2022; 11(14): 2183. doi:10.3390/cells11142183.
15. Armaghany T, Wilson JD, Chu Q, Mills G. Genetic alterations in colorectal cancer. Gastrointest Cancer Res. 2012; 5(1): 19-27.